David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “David is one of the most accomplished leaders in eye care, with a strong track r ...

Royal Philips is targeting an operating margin around the mid-teens by 2028 as the medical technology firm seeks to draw a line under a costly recall of its sleep apnea devices https://t.co/KeVOdGji3E ...

Market Overview - Major U.S. index futures indicate a higher open on Monday, suggesting a potential recovery from last Friday's significant weakness, particularly in tech stocks [1] - Trading activity may remain subdued as traders anticipate key U.S. economic data releases in the coming days [1] Economic Data Releases - The monthly jobs report for November and October retail sales data are set to be released on Tuesday, while consumer price inflation data for November is scheduled for Thursday [2] - These reports could influence the outlook for interest rates following the Federal Reserve's recent monetary policy announcement, which included a quarter-point rate cut [2] Stock Market Performance - On Friday, stocks experienced a notable decline, with the Nasdaq dropping 398.69 points (1.7%) to 23,195.17 and the S&P 500 falling 73.59 points (1.1%) to 6,827.41 [3] - The Dow posted a more modest loss of 245.96 points (0.5%) to 48,458.05 after reaching a new record intraday high earlier in the session [4] - For the week, the Dow increased by 1.1%, while the S&P 500 decreased by 0.6% and the Nasdaq fell by 1.6% [4] Sector Performance - Broadcom (AVGO) led the tech sector lower, plunging over 11% despite reporting better-than-expected fiscal fourth-quarter results and providing positive guidance [5] - Other tech stocks, including Micron Technology (MU), Oracle, AMD, and Nvidia, also saw significant declines, indicating a continued rotation out of tech stocks [5] - The NYSE Arca Computer Hardware Index experienced a 5.2% drop, reflecting poor performance in computer hardware stocks [7] International Market Reactions - Asian stocks fell as investors expressed concerns over tech valuations and reacted to disappointing economic data from China [10] - Chinese industrial production grew 4.8% year-on-year in November, missing forecasts, while retail sales rose only 1.3%, significantly below expectations [12] - The Japanese market also declined, with the Nikkei 225 Index dropping 1.3% amid concerns over tech share valuations [13] European Market Trends - European stocks mostly moved higher ahead of a busy week for U.S. economic data and central bank decisions, with the German DAX Index up by 0.3% and the U.K.'s FTSE 100 Index rising by 1.0% [18][19] - However, technology company Royal Philips and pharmaceutical firm Sanofi faced declines due to corporate news impacting their stock prices [19][20]

Royal Philips’s slightly increased its adjusted operating profitability outlook, as the impact of the trade war was not as severe as it feared https://t.co/hv7FRjP54H ...

Core Insights - Royal Philips was the leading applicant in medical technology at the European Patent Office in 2024, filing 594 Medtech patent applications, highlighting its commitment to healthcare transformation through informatics and AI [3][7] - The company aims to improve the health and well-being of 2.5 billion people by 2030, having already improved the lives of nearly 2 billion people in 2024 [5] - Philips invested approximately EUR 1.7 billion in R&D in 2024, representing over 9% of sales, which is significantly above the industry average [9] Innovation and Technology - Philips launched several informatics and AI-powered innovations in 2024, including the Azurion image-guided therapy system and FDA-cleared AI tools for cardiovascular imaging [12] - The company has a robust intellectual property portfolio with 50,500 patent rights, 30,500 trademarks, and 150,000 design rights, reinforcing its innovation leadership [9] - Philips was included in the Clarivate Top 100 Global Innovators 2025, marking its 12th consecutive year in this assessment [8] Market Position - Philips generated sales of EUR 18 billion in 2024 and employs approximately 67,800 people, with operations in over 100 countries [10] - The company maintains its 1 global position in cardiovascular ultrasound, supported by advancements in automation and productivity [12]